Skip to content
Screener

DexCom DXCM Q1 2026 earnings

Reported April 30, 2026 · After market close

Revenue$1.2BBeat by $17.2M
EPS$0.56Beat by $0.09
Revenue estimate$1.2B
EPS estimate$0.47

Next report

Oct 29, 2026 (in 2 months)
Revenue estimate$1.3B
EPS estimate$0.66

Financials

Q1 2026

Income statement

See full
Revenue$1.2B+15.0%
Gross profit$750.3M+27.4%
Operating income$255.3M+90.9%
Net income$199.5M+89.3%
EPS (diluted)$0.51+88.9%

Balance sheet

See full
Cash & equivalents$1.1B+23.4%
Total debt$143.0M+2.2%
Total equity$3.0B+30.5%
Total assets$6.6B-1.8%

Cash flow

See full
Operating cash flow$525.6M+186%
CapEx$76.6M-12.0%
Free cash flow$449.0M+364%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$24.17B-9.7%
Enterprise value$23.19B-10.8%
P/E26×-24.1×
P/S5×-1.4×

Profitability

See full
Gross margin61.5%+2.1pp
Operating margin21.4%+6.2pp
Net margin19.3%+6.4pp
FCF margin29.7%+15.8pp

Returns & leverage

See full
Return on equity35.6%+11.9pp
Debt / equity0×0.0×
Current ratio1.9×+0.4×

FAQ

When did DexCom report Q1 2026 earnings?
DexCom (DXCM) reported Q1 2026 earnings on April 30, 2026 after market close.
What were DexCom's Q1 2026 revenue and EPS?
DexCom reported revenue of $1.2B and eps of $0.56 for Q1 2026.
Did DexCom beat estimates in Q1 2026?
Revenue beat the consensus estimate of $1.2B by $17.2M. EPS beat the consensus estimate of $0.47 by $0.09.
How did DexCom's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 15.0% from $1.0B a year earlier and eps grew 75.0% from $0.32.
Where can I find DexCom's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001093557-26-000072) and the 10-Q periodic report (0001093557-26-000073) directly on SEC EDGAR. The filing index links above go to sec.gov.